Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT06124976
Recruiting
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
Phase 2/3 · Canada · 8 sites
Registry update: 3 Aug 2026
NCT06341400
Recruiting
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Phase 1/2 · China · 1 site
Registry update: 8 Oct 2026
NCT06378242
Recruiting
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Phase 1/2 · China · 6 sites
Registry update: 11 Jul 2024
NCT06228066
Recruiting
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2 · United States · 1 site
Registry update: 16 Oct 2026
NCT06239194
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2 · United States · 6 sites
Registry update: 15 Oct 2026
NCT06332755
Recruiting
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
Phase 1 · United States · 1 site
Registry update: 24 Nov 2025
NCT06889623
Recruiting
Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
Not applicable · China · 1 site
Registry update: 21 Mar 2025
NCT06548529
Recruiting
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
Not applicable · China · 1 site
Registry update: 23 Aug 2024
NCT06405425
Recruiting
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · China · 1 site
Registry update: 23 Jul 2026
NCT06451497
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Phase 1 · United States · 3 sites
Registry update: 2 Apr 2026
NCT06262516
Recruiting
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
Not applicable · United States · 4 sites
Registry update: 1 Oct 2026
NCT06364956
Recruiting
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
Phase 1/2 · China · 8 sites
Registry update: 11 Aug 2025
NCT06373055
Recruiting
Prediction of Therapeutic Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer Patients Using Spatial Transcriptomics
Not applicable · South Korea · 1 site
Registry update: 18 Apr 2024
NCT06265285
Recruiting
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 · United States · 1 site
Registry update: 2 Oct 2026
NCT06349642
Recruiting
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Not applicable · United States · 3 sites
Registry update: 12 Mar 2026
NCT05037279
Recruiting
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Phase 3 · Canada · 6 sites
Registry update: 20 Mar 2026
NCT06319820
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Argentina, Austria, Belgium, Brazil, China, Czechia, Germany, Denmark, Spain, France, United Kingdom, Hong Kong, Ireland, Israel, Italy, Japan, South Korea, Poland, United States · 193 sites
Registry update: 3 Nov 2026
NCT07750470
Recruiting
Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer
Not applicable · Italy · 1 site
Registry update: 6 Aug 2026
NCT06330064
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Phase 1/2 · Argentina, Australia, Belgium, Brazil, Chile, Germany, Spain, France, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Taiwan, United States · 120 sites
Registry update: 26 Oct 2026
NCT06351904
Recruiting
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Phase 1 · Australia · 3 sites
Registry update: 11 Sept 2025

Ordered by registry start date. Freshness and sponsorship never change the order.